← Back to Search

Beta Blocker

Timolol Ophthalmic Suspension 0.5 Percent for Ocular Hypertension

Phase 2
Waitlist Available
Research Sponsored by Betaliq, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 15: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 42: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 84: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing new eye drops (nebivolol) against an existing one (timolol) in patients with glaucoma or high eye pressure. It aims to see if the new drops are safe and effective in lowering eye pressure. The drops work by reducing the pressure inside the eye to protect vision.

Eligible Conditions
  • Ocular Hypertension
  • Open-Angle Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 15: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 42: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 84: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 15: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 42: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes; day 84: 8 am ± 30 minutes, 2 hours post-dose ± 30 minutes, 4 pm ± 30 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Intraocular Pressure Over 84 Days
Secondary study objectives
Intraocular Pressure: Change From Baseline at All Time Points at Each Visit
Intraocular Pressure: Change From Baseline in Diurnal IOP at Each Visit

Side effects data

From 2022 Phase 2 trial • 226 Patients • NCT04910100
7%
Instillation site reaction
4%
Intraocular pressure increased
2%
Instillation site pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Nebivolol Ophthalmic Suspension 1 Percent
Nebivolol Ophthalmic Suspension 0.5 Percent
Timolol Ophthalmic Suspension 0.5 Percent
Timolol Ophthalmic Solution 0.5 Percent

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Timolol Ophthalmic Suspension 0.5 PercentExperimental Treatment1 Intervention
Administered twice daily to both eyes for 84 days (12 weeks)
Group II: Nebivolol Ophthalmic Suspension 1 PercentExperimental Treatment1 Intervention
Administered twice daily to both eyes for 84 days (12 weeks)
Group III: Nebivolol Ophthalmic Suspension 0.5 PercentExperimental Treatment1 Intervention
Administered twice daily to both eyes for 84 days (12 weeks)
Group IV: Timolol Ophthalmic Solution 0.5 PercentActive Control1 Intervention
Administered twice daily to both eyes for 84 days (12 weeks)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nebivolol Ophthalmic Suspension 1 Percent
2021
Completed Phase 2
~230
Nebivolol Ophthalmic Suspension 0.5 Percent
2021
Completed Phase 2
~230
Timolol Ophthalmic Suspension 0.5 Percent
2021
Completed Phase 2
~230

Find a Location

Who is running the clinical trial?

Summit Analytical, LLCUNKNOWN
Trial Runners, LLCOTHER
3 Previous Clinical Trials
365 Total Patients Enrolled
Betaliq, Inc.Lead Sponsor
~49 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top